Drug Candidate Marketplace

Drug Candidate Marketplace lists the information of drug candidates, therapeutic targets and drug discovery technologies. Visitors can use search functions based on the interests and needs. If you have a drug candidates, therapeutic targets and drug discovery technologies that you are interested in and would like to gain more information, please contact us by clicking the inquiry button. After consenting to the terms of condition and use of our services, the requested information will be provided to you.

Date Candidate Mechanism of action Indication Route Development stage Note
08/07/18 GEM033 Inhibitors of bacterial resistance mechanisms Gram-negative MDR bacterial infections, lung infections in cystic fibrosis (CF) patients see Note Preclinical Restore effectiveness of shelved antibiotics.
Lower the effective dose of antibiotics.
Mitigate antibiotic resistance.
Disrupt biofilm-based infections.
Over 1,000 compounds with lead compounds for each indication identified.

Route : Intravenous, Aerosol, Topical
Contact
07/26/18 GEM032 Calcium release-activated calcium channel inhibitor Respiratory & immuno-inflammatory diseases Oral Phase 1 - Preclinical study demonstrated the therapeutic potential in respiratory diseases causally associated with allergic inflamation.
- Phase 1 SAD/MAD study were completed.
Contact
07/26/18 GEM031 Calcium release-activated calcium channel inhibitor Lymphomas & Solid cancer Oral Phase 1 - Demonstrated preclinical activity in a broad range of cancers.
- Phase 1 dose-escalation study in patients with relapsed or refractory lymphomas is ongoing.
Contact
07/26/18 GEM030 PI3K δ/γ dual inhibitor Hematological malignancies, T cell Lymphoma, Hodgkin Lymphoma Oral Phase 2 - Highly specific dual PI3K δ/γ inhibitor with nano‐molar inhibitory potency
- Single-agent and combination with immune checkpoint inhibitor programs
- Inhibits primary patient leukemic/lymphoma cells
- Dose escalation study demonstrated an acceptable safety and tolerability with promising clinical activity
Contact
07/20/18 GEM029 A cancer stem cell-associated transcription factor inhibitor Malignant gliomas including glioblastoma (GBM) Oral Phase 1 ready -Directly kills the cancer stem cells.
-Significantly improves survival in orthotopic GBM PDX models.
-Inhibits tumor growth in a mouse implanted with GBM cells and the growth inhibition is augmented by combination with temozolomide/radiation.
-No significant toxicities are identified at therapeutic doses.
Contact
07/09/18 GEM028 miRNA targeting refractory colon cancer with mutated K-ras and refractory pancreatic cancer pancreatic cancer colon cancer IV Preclinical The miRNA regulates K-ras, Bcl2, survivin, and NF-kB and demonstrate excellent antitumor effect in vitro and in vivo. Contact
07/09/18 GEM027 miRNA targeting refractory colon cancer with mutated K-ras colon cancer IV Preclinical The miRNA regulates EGFR signaling pathway by directly inhibiting of both KRAS and AKT1 and demonstrate excellent antitumor effect in vitro and in vivo. Contact
07/09/18 GEM026 siRNA suppressing the expression of novel cancer stem cell gene "Gene A" Cancer IV Preclinical -Novel cancer stem cell gene "Gene A", which was discovered by single cell analysis of cancer stem cell, shows character as follows.
1.Superior cancer stem cell diagnostic marker than known cancer stem cell marker CD44v9
2.SiRNA targeting Gene A demonstrate excellent antitumor effect with currnet medicines.
Contact
07/09/18 GEM025 miRNA suppressing the expression of a protein characteristic of pancreatic cancer stem cells pancreatic cancer IV Preclinical Excellent antitumor effect was demonstrated in uniquely established pancreatic cancer stem cell model in vitro and in vivo. Contact
07/09/18 GEM024 Selective inducer of apoptosis through modulation of NF-kB Oral Squamous Cell Carcinoma Phase 2 ready (FDA approved IND) -First-in-class, combination therapeutic that simultaneously upregulates a cluster of genes promoting cell death and downregulates a cluster of genes promoting survival of cancer cells.
-Phase 1 in USA results showed no significant AE and dose-dependent modulation of key biomarkers involved in disease pathogenesis.

Route : Oral, pastille based topical delivery
Contact